Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

Abstract: A system for in-memory computing comprises a volatile memory comprising at least a first layered subarray, wherein each subarray comprises a plurality of memory cells, and a plurality of sub-sense amplifiers connected to a read bitline of the first subarray of the memory, configured to compare a measured voltage of the read bitline to at least one threshold and provide at least one binary output corresponding to a logic operation based on whether the voltage of the read bitline is above or below the threshold. A method for in-memory computing is also disclosed.

Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: Disclosures herein are directed to methods and compositions for the detection of and screening for mutations that convey phenotypic properties in a protein such as, for example, drug-resistance. Embodiments of the present disclosure include lentiviral-based compositions for enhanced mutagenesis and screening of genes encoding proteins of interest that confer drug resistance according to methods disclosed herein.

Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Abstract: A method of calculating an abundance of an mRNA sequence within a gene comprises storing an index table of the gene in a non-volatile memory, obtaining a short read of the mRNA sequence, generating a set of input fragments from the mRNA sequence, initializing a compatibility table in a volatile memory, for each input fragment in the set of input fragments, searching for an exact match of the input fragment in the index table, calculating a final result from the compatibility table, and calculating an abundance of the mRNA sequence in the gene by aggregating the transcripts compatible with the short read, wherein the calculating step is performed on the same integrated circuit as the non-volatile memory. A system for in-memory calculation of an abundance of an mRNA sequence within a gene is also disclosed.

Abstract: A microelectromechanical (MEMS) device is provided. The MEMS device comprises a substrate and a movable structure flexurally connected to the substrate, capable of moving in relation to the substrate, wherein the movable structure further comprising two or more segments having at least one mechanical connection between said segments to provide structural integrity of the moving structure; and wherein the at least one mechanical connection electrically isolates at least two segments.

Abstract: Disclosed herein are methods and systems for membrane carbonation for cultivating microalgae and other microorganisms that utilize a gaseous substrate, as well as to upgrade the quality of mixed-gas streams.

Abstract: The present invention includes an intraoral tool, including one or more selected solid or inflatable inserts targeted to provide a low load prolonged stretch to orofacial musculature that may be coupled to tool handle or tool mounting bracket, wherein the intraoral tool is configured for a delivery of intraoral treatment, such as a stretch to a patient's facial injury or disorder and configured to permit manipulation of the insert in the patient's mouth.

Abstract: Provided herein is a surgical instrument comprising a cap having a first and second aperture extending therethrough, a first extendable and retractable member having a distal end coupled to a first coupling, a first arm extending from the first coupling and pivotable with respect to the distal end of the first member, and a second arm connected to the first arm through a second coupling and pivotable, with respect to the first arm, a second extendable and retractable member having a distal end coupled to a third coupling, a third arm extending from the second coupling, the third arm pivotable, with respect to the distal end of the second member, and a fourth arm connected to the third arm through a fourth coupling and pivotable, with respect to the third arm, a first end effector connected to the second arm and a second end effector connected to the fourth arm.

Abstract: In one aspect, the present disclosure provides for novel compositions of matter comprising multi domain peptide (MDP) hydrogels and cyclic dinucleotides (CDNs). Also disclosed are method of using such compositions in the treatment of cancer, including in particular the treatment of head and neck cancers, such as those resistant to CDN therapy.

Abstract: The disclosure provides methods for treating or limiting development age-related macular degeneration, comprising (a) a GPR143 receptor agonist, including but not limited to L-DOPA, L-DOPA analogues, or a pharmaceutically acceptable salt thereof, and (b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof, and related compositions.

Abstract: Various embodiments disclosed relate to methods and compositions for antimicrobial treatment. In various embodiments, the present invention provides a method of antimicrobial treatment. The method includes at least one of exposing at least one microbe to a magnetic field, and contacting the at least one microbe with at least one nanoparticle including iron.

Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

Abstract: Peptide analogues of ?-amyloid and methods of using said analogues for neuroprotection are described herein. The ?-amyloid peptide analogues have a sequence that is at least 50% identical to an N-terminal ?-amyloid core fragment. A pharmaceutical composition of the ?-amyloid peptide analogues in a pharmaceutically acceptable carrier can be administered to a subject for neuromodulation. The ?-amyloid peptide analogues, while lacking neurotoxicity, effectively provides for protective activity against ?-amyloid toxicity.

Abstract: Provided herein are methods for classifying how a subject having a cancer will respond to immunotherapeutic (IT) therapy based on the subject's immunosignature or frameshift signature. Also provided herein are methods for classifying a subject having a cancer as having a good prognosis or a poor prognosis based on the subject's immunosignature or frameshift signature.

Abstract: In one aspect, molecular sensors and methods of making molecular sensors are described herein. In some embodiments, such a sensor comprises a first layer having a dual nanohole structure and a second layer having at least one nanopore. In some embodiments, the first and second layer define a chip of the sensor. In another aspect, methods of sensing are described herein, which in some embodiments comprise (i) providing a test sample comprising complexed and/or non-complexed biomolecules; (ii) contacting the test sample with the first layer of the molecular sensor; (iii) irradiating the dual nanohole structure of the sensor with a beam of electromagnetic radiation; (iv) optically trapping the biomolecules in the dual nanohole structure and measuring a surface plasmon resonance; (v) applying an electric field across the nanopore of the sensor; and (vi) measuring change in current across the nanopore during one or more translocation events of the biomolecules.

Abstract: Cellulose materials and methods of making the cellulose materials are described herein. The method can include contacting a cotton fabric with an oxidizing system to obtain an oxidized cotton material and processing the oxidized cotton material to form the cellulose material. The oxidizing system can include an aqueous mixture of a N-oxyl compound and a hypochlorite compound. During oxidation, the p11 of the aqueous mixture can be maintained at from 8.5 to 11. Cellulose products can be formed from the cellulose materials. For example, the cellulose products can be used to form a packaging material, a biomedical device or implant, a drug delivery material, a fiber, a textile material, a template for electronic components, or a separation membrane. Methods of making the cellulose product include dissolving or suspending an active ingredient in a medium comprising the cellulose material.

Abstract: A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.